In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This analysis is based on information available up to January 13, 2025, and reflects the most recent data and analyst perspectives on BioCryst Pharmaceuticals, Inc. Gain an edge in your investment ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on BCRX: BioCryst Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

The press release states that BioCryst Pharmaceuticals anticipates approaching quarterly earnings per share profitability during the latter part of the fiscal year ending December 31, 2025.

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

BioCryst (NASDAQ:BCRX) released its preliminary 2024 revenue results, along with guidance for 2025. The company said it expects to report 2024 net revenue of $450M, up 36% from the prior year ...